FAAH Availability in Psychiatric Disorders: A PET Study

Status Terminated

Clinical Trial Summary

The aim of the present study is to examine Fatty Acid Amide Hydrolase (FAAH) availability in humans, including healthy individuals and across a spectrum of psychiatric disorders in which alterations in the endocannabinoid system are observed.

Clinical Trial Description

This study involves in vivo examination of FAAH availability, implicated both in the pathophysiology and therapeutics of disorders including PTSD, substance use disorders (e.g., alcohol use disorder, cannabis/cannabinoid use disorder, nicotine use disorder), psychotic disorders including schizophrenia, and mood disorders. The endocannabinoid system is a neuromodulatory system that has been implicated across a wide range of psychiatric disorders and may be implicated in the regulation of mood, appetitive behaviors, sleep, and cognition. Thus, alterations in the ECS have wide ranging implications. Finally, the ECS is being explored as a novel therapeutic target for several psychiatric disorders. Additionally, the test/retest reliability of the radiotracer, [11C]MK-3168, will be studied in up to 10 healthy control individuals. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04404712
Study type	Interventional
Source	Yale University
Contact
Status	Terminated
Phase	Early Phase 1
Start date	September 23, 2020
Completion date	June 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04788004` - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting	`NCT05684094` - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function	N/A
Completed	`NCT03406039` - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems	N/A
Completed	`NCT03573167` - Mobile Phone-Based Motivational Interviewing in Kenya	N/A
Completed	`NCT04817410` - ED Initiated Oral Naltrexone for AUD	Phase 1
Active, not recruiting	`NCT04267692` - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders	N/A
Completed	`NCT03872128` - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders	Phase 1
Recruiting	`NCT06030154` - Amplification of Positivity for Alcohol Use	N/A
Active, not recruiting	`NCT05419128` - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19	N/A
Completed	`NCT04564807` - Testing an Online Insomnia Intervention	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Completed	`NCT04203966` - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting	`NCT05861843` - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Enrolling by invitation	`NCT04128761` - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder	N/A
Not yet recruiting	`NCT06337721` - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults	N/A
Enrolling by invitation	`NCT02544581` - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare	N/A
Completed	`NCT02511886` - A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder	Phase 2
Active, not recruiting	`NCT02185131` - Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.	Phase 2
Completed	`NCT01916941` - Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin	N/A
Terminated	`NCT01408641` - Topiramate for Alcohol Use in Posttraumatic Stress Disorder	N/A